Evidence map›Paper›PMID 34805743›Full record

ArticleJNCI cancer spectrum2021

Treatment Patterns, Outcomes, and Costs Associated With Localized Upper Tract Urothelial Carcinoma.

Katherine E Fero, Yong Shan, Patrick M Lec, Vidit Sharma, Aditya Srinivasan, Giri Movva, Jacques Baillargeon, Karim Chamie, Stephen B Williams

Open access · goldAbstract read
In one paragraph

Article in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Katherine E FeroDepartment of Urology, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-2155-960X
Yong ShanDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA.
Patrick M LecDepartment of Urology, University of California Los Angeles, Los Angeles, CA, USA.
Vidit SharmaDepartment of Urology, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-4715-5451
Aditya SrinivasanDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA.
Giri MovvaDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA.
Jacques BaillargeonDepartment of Medicine, Division of Epidemiology, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Karim ChamieDepartment of Urology, University of California Los Angeles, Los Angeles, CA, USA.
Stephen B WilliamsDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Upper tract urothelial carcinoma (UTUC) is a heterogeneous disease that presents a clinical management challenge for the urologic surgeon. We assessed treatment patterns, costs, and survival outcomes among patients with nonmetastatic UTUC. Methods: We identified 4114 patients diagnosed with nonmetastatic UTUC from 2004 to 2013 in the Survival Epidemiology, and End Results-Medicare population-based database. Patients were stratified into low- or high-risk disease groups. Median total costs from 30 days prior to diagnosis through 365 days after diagnosis were compared between groups. Overall and cancer-specific survival were evaluated using Cox proportional hazards regression. All statistical tests were 2-sided. Results: After risk stratification, 1027 (24.9%) and 3087 (75.0%) patients were classified into low- vs high-risk UTUC groups. Most patients underwent at least 1 surgical intervention (95.1%); 68.4% underwent at least 1 endoscopic intervention. Patients diagnosed with high- vs low-risk UTUC were more likely to undergo nephroureterectomy (83.6% vs 72.0%; Conclusions: UTUC continues to be managed primarily with nephroureterectomy, regardless of risk stratification, and patients with high-risk UTUC have worse overall and cancer-specific survival. Substantial costs are associated with management of low- and high-risk UTUC, with the latter being more costly up to 1 year from diagnosis.

Indexed as

Carcinoma, Transitional CellKidney NeoplasmsNephroureterectomyUreteral NeoplasmsAgedAged, 80 and overAmbulatory Surgical ProceduresCosts and Cost AnalysisFemaleHospitalizationHumansMaleMedicareOrgan Sparing TreatmentsProportional Hazards ModelsRetrospective Studies

Identifiers

PMID34805743
PMCPMC8599752
OpenAlexW3202878806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.